Education
About Us
Working with TipRanks
Follow Us
Akso Health Group Sponsored ADR (AHG)
NASDAQ:AHG
Top Page
Akso Health Group Sponsored ADR
(NASDAQ:AHG)
Select Model
Select Model
Rating:45Neutral
Price Target:―
The overall stock score for Akso Health Group is low due to significant challenges in profitability and revenue stability. The technical analysis points to negative momentum, while the valuation is weak with a negative P/E ratio. The recent market reaction post-earnings call was negative, further impacting the score. Without positive corporate events or earnings call highlights, the outlook remains cautious.
Akso Health Group Sponsored ADR (AHG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$878.07M
Dividend YieldN/A
Average Volume (3M)21.06K
Price to Earnings (P/E)―
Beta (1Y)-0.28
Revenue Growth510.69%
EPS Growth-145.92%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryFinancial - Credit Services
Share Statistics
EPS (TTM)-0.06
Shares Outstanding549,200,900
10 Day Avg. Volume27,668
30 Day Avg. Volume21,060
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)1.69
Price to Sales (P/S)22.76
P/FCF Ratio328.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Akso Health Group Sponsored ADR Business Overview & Revenue Model
Company DescriptionAkso Health Group operates a social e-commerce mobile platform in China. The company operates Xiaobai Maimai App, which offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment products, housewares, home appliances, etc. It also offers consultancy and information technology support services; and trades in branded products, as well as promotes products. The company was formerly known as Xiaobai Maimai Inc. and changed its name to Akso Health Group in December 2021. Akso Health Group was founded in 2014 and is headquartered in Beijing, China. As of July 13, 2021, Akso Health Group operates as a subsidiary of Webao Limited.
How the Company Makes MoneyAkso Health Group generates revenue through a diversified model that includes providing healthcare services such as traditional Chinese medicine consultations, wellness management programs, and integrated healthcare solutions. The company collaborates with healthcare institutions and leverages its expertise in both traditional and modern medical practices to offer a wide range of services. Revenue streams are primarily driven by patient consultations, treatment programs, and strategic partnerships with healthcare providers and technology firms that enhance its service offerings. Key factors contributing to its earnings include the growing demand for alternative medicine, expansion into new markets, and the integration of technology in healthcare services to improve efficiency and patient outcomes.
Akso Health Group Sponsored ADR Financial Statement Overview
Summary
Akso Health Group faces challenges with profitability and revenue stability. While its balance sheet shows a strong equity position, the lack of comprehensive debt information introduces uncertainty in financial leverage assessment. Cash flow has improved recently, but historical volatility poses a risk. Overall, the company needs to address its revenue and profitability issues to enhance financial health.Income Statement
The company has experienced significant revenue volatility, with a steep decline in recent years. The net profit margin is severely negative due to substantial net losses, indicating poor profitability. There is no gross profit data to assess cost efficiency, and EBIT/EBITDA margins are unavailable for additional insights.40
Negative
Balance Sheet
The equity ratio is strong, indicating a solid equity base relative to total assets. However, the lack of debt data prevents a full assessment of leverage. Stockholders' equity has increased recently, but the company has a history of equity fluctuations.55
Neutral
Cash Flow
The company has shown inconsistent operating cash flows, with recent positive figures. Free cash flow has been volatile, with significant growth over the past year, albeit from a low base. The cash flow to net income ratio is unreliable due to negative net income.50
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.78M | 14.78M | 2.41M | 13.18M | 6.00M | 1.75M |
| Gross Profit | -281.53K | -281.53K | 122.13K | 1.27M | 605.13K | 1.21M |
| EBITDA | -1.77M | -1.77M | -9.08M | -14.25M | -3.19M | -28.90M |
| Net Income | -134.98M | -134.98M | -9.46M | -1.36M | -16.85M | -34.83M |
Balance Sheet | ||||||
| Total Assets | 214.95M | 214.95M | 142.02M | 20.46M | 50.68M | 31.69M |
| Cash, Cash Equivalents and Short-Term Investments | 176.23M | 176.23M | 85.17M | 7.92M | 18.43M | 15.13M |
| Total Debt | 81.74K | 81.74K | 2.00M | 9.69M | 37.20M | 10.00M |
| Total Liabilities | 15.80M | 15.80M | 3.59M | 11.62M | 38.39M | 14.41M |
| Stockholders Equity | 199.12M | 199.12M | 138.37M | 8.73M | 12.28M | 17.27M |
Cash Flow | ||||||
| Free Cash Flow | 1.02M | 1.02M | 1.35M | -3.25M | -8.63M | 10.06M |
| Operating Cash Flow | 1.18M | 1.18M | 1.35M | -3.25M | -8.63M | 10.06M |
| Investing Cash Flow | -105.91M | -105.91M | -54.72M | 18.47M | -19.96M | -662.00 |
| Financing Cash Flow | 195.88M | 195.88M | 131.65M | -27.51M | 34.78M | -9.04M |
Akso Health Group Sponsored ADR Technical Analysis
Negative
1.57
Price Trends
1.70
Negative
1.67
Negative
1.49
Positive
Market Momentum
-0.02
Negative
44.54
Neutral
38.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AHG, the sentiment is Negative. The current price of 1.57 is below the 20-day moving average (MA) of 1.64, below the 50-day MA of 1.70, and above the 200-day MA of 1.49, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 44.54 is Neutral, neither overbought nor oversold. The STOCH value of 38.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AHG.
Akso Health Group Sponsored ADR Risk Analysis
Akso Health Group Sponsored ADR disclosed 55 risk factors in its most recent earnings report. Akso Health Group Sponsored ADR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
The approval of the China Securities Regulatory Commission, or the CSRC, may be required in connection with an offering under PRC rules, regulations, or policies, and, if required, we cannot predict whether or how soon we will be able to obtain such approval. As a result, both you and us fact uncertainty about future actions by the PRC government that could significantly affect our business, our listing on Nasdaq, financial condition and results of operations. Q1, 2023
Akso Health Group Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $1.50B | 3.99 | 18.75% | 4.60% | 8.41% | 34.76% | |
75 Outperform | $453.63M | 2.56 | 13.64% | 8.30% | 12.69% | -35.36% | |
72 Outperform | $736.99M | 3.46 | 14.86% | 7.10% | 3.11% | 95.40% | |
64 Neutral | $786.00M | 11.22 | 4.57% | ― | -39.25% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $878.07M | -3.36 | -79.90% | ― | 510.69% | -145.92% | |
44 Neutral | $559.11M | ― | -0.09% | ― | 93.57% | -106.02% |
* Healthcare Sector Average
AHG
Akso Health Group Sponsored ADR
1.57
0.71
82.56%
YRD
Yiren Digital
5.30
-0.37
-6.53%
QD
Qudian
4.75
2.36
98.74%
FINV
FinVolution Group
6.02
0.21
3.61%
LX
Lexinfintech Holdings
4.28
0.80
22.99%
FOA
Finance of America Companies
22.32
6.41
40.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.